Indolent Non-Hodgkin Lymphoma Clinical Trial
— ELiPSE-1Official title:
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | August 2027 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). 2. Must have met the following criteria for prior treatment: 1. Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor [CAR] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator. 2. Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator. 3. Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies. 3. Measurable disease on screening evaluations. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Adequate organ function. 6. Life expectancy of =12 weeks. Exclusion Criteria: 1. Any condition that confounds the ability to interpret data from the study. 2. Central nervous system (CNS)-only involvement by malignancy. (Note: participants with secondary CNS involvement are allowed.) 3. Prior allogeneic stem cell transplant. 4. Presence of clinically significant CNS pathology. 5. Other comorbid conditions defined in the protocol. 6. Use of prohibited medications within the washout period defined in the protocol. |
Country | Name | City | State |
---|---|---|---|
United States | Levine Cancer Institute | Charlotte | North Carolina |
United States | Oncology Hematology Care, Inc-Kenwood | Cincinnati | Ohio |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | UT Southwestern | Dallas | Texas |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | Houston Methodist Research Institute | Houston | Texas |
United States | University of Kentucky - Markey Cancer Center | Lexington | Kentucky |
United States | University of Southern California - Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Virginia Oncology Associates | Norfolk | Virginia |
United States | University of California San Diego, Moores Cancer Center | San Diego | California |
United States | Swedish Cancer Institute | Seattle | Washington |
United States | Medstar Georgetown University Hospital | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Century Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity | Up to 28 days | ||
Primary | Recommended Phase 2 Regimen (RP2R) as Recommended by the Safety Review Committee (SRC) | Up to 28 days | ||
Secondary | Complete Response Rate (CRR) Based on Percentage of Participants Achieving Complete Response (CR) | CRR will be determined using Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. | Up to 2 years | |
Secondary | Objective Response Rate (ORR) Based on Percentage of Participants Achieving CR or Partial Response (PR) | ORR will be determined using Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. | Up to 2 years | |
Secondary | Duration of Response (DOR) | DOR is defined as time from first response (CR or PR) to the first documentation of progressive disease (PD) or death. | Up to 2 years | |
Secondary | Time to Treatment Response (TTR) | TTR is defined as time from first CNTY-101 infusion to the first documentation of response (CR or PR). | Day 1 up to 2 years | |
Secondary | Progression-Free Survival (PFS) | PFS is defined as time from first CNTY-101 infusion to the first documentation of PD, or death from any cause, whichever occurs first | Day 1 up to 2 years | |
Secondary | Overall Survival (OS) | OS is defined as time from CNTY-101 infusion to death. | Day 1 up to 2 years | |
Secondary | Cmax: Maximum Observed Plasma Concentration for CNTY-101 | Day 1 up to 2 years | ||
Secondary | Tmax: Time to Reach the Maximum Plasma Concentration for CNTY-101 | Day 1 up to 2 years | ||
Secondary | t1/2: Terminal Disposition Phase Half-life for CNTY-101 | Day 1 up to 2 years | ||
Secondary | AUC: Area under the Concentration-time Curve for CNTY-101 | Day 1 up to 2 years | ||
Secondary | Percentage of Participants With at Least one Treatment Emergent Adverse Event (TEAE) | Day 1 up to 2 years | ||
Secondary | Percentage of Participants With Clinically Significant Laboratory Abnormalities | Day 1 up to 2 years | ||
Secondary | Time to Treatment Initiation | Time to treatment initiation is defined as the time from enrollment in the study to first CNTY-101 infusion. | Enrollment to first CNTY-101 infusion (up to approximately 2 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
Completed |
NCT04038359 -
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT04136756 -
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
Completed |
NCT02242045 -
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
|
Phase 1 | |
Completed |
NCT01231412 -
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
|
Phase 3 | |
Active, not recruiting |
NCT02566304 -
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT04223765 -
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
Phase 1 | |
Active, not recruiting |
NCT03035331 -
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05876923 -
The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
|
N/A | |
Completed |
NCT00723099 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03105336 -
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Withdrawn |
NCT04372641 -
Testing the Safety of CB-5339 in Patients With Cancer
|
Phase 1 | |
Completed |
NCT01882803 -
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04323956 -
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT04464200 -
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
|
Phase 1 | |
Recruiting |
NCT05783596 -
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03749018 -
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03884998 -
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
|
Phase 1 | |
Terminated |
NCT01944943 -
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 2 |